Immune systems develop specific genes to combat common bacteria such as those found in food, new research shows.
Novo Holdings to purchase drug manufacturer Catalent for $16.5 billion, a deal that could expand Wegovy production
LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give
February 5, 2024